成功治疗 B 细胞急性淋巴细胞白血病患者延长疗程的瑞德西韦和奈玛特韦/利托那韦治疗的严重 2019 冠状病毒病下呼吸道疾病。
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
机构信息
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
出版信息
Clin Infect Dis. 2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868.
Abstract
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.
摘要
一位患有 B 细胞急性淋巴细胞白血病（ALL）和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的患者在感染后 5 个月时出现持续性、进行性肺炎伴病毒血症，尽管使用了单克隆抗体、静脉（IV）瑞德西韦和长期口服类固醇。使用奈玛特韦/利托那韦 20 天和静脉注射瑞德西韦 10 天导致完全康复。
相似文献
1
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Clin Infect Dis. 2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868.
2
Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report.
J Infect Public Health. 2024 Oct;17(10):102526. doi: 10.1016/j.jiph.2024.102526. Epub 2024 Aug 24.
3
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Hematol Oncol. 2023 Dec;41(5):904-911. doi: 10.1002/hon.3206. Epub 2023 Jul 15.
4
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Viruses. 2023 Oct 8;15(10):2066. doi: 10.3390/v15102066.
5
Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
J Infect Chemother. 2024 Jul;30(7):659-663. doi: 10.1016/j.jiac.2023.12.014. Epub 2024 Jan 5.
6
Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
Viruses. 2023 Jul 19;15(7):1577. doi: 10.3390/v15071577.
7
Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Infect Dis (Lond). 2023 Aug;55(8):585-589. doi: 10.1080/23744235.2023.2223274. Epub 2023 Jun 18.
8
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Acta Med Indones. 2022 Oct;54(4):638-644.
9
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
J Chemother. 2023 Nov;35(7):623-626. doi: 10.1080/1120009X.2023.2196917. Epub 2023 Apr 27.
10
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
N Engl J Med. 2023 Feb 2;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub 2022 Dec 28.
引用本文的文献
1
Rituximab in the COVID-19 era: The impact of albumin and IgG on patients with immune-mediated inflammatory diseases.
Clin Rheumatol. 2025 Jul 31. doi: 10.1007/s10067-025-07598-3.
2
Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report.
J Egypt Natl Canc Inst. 2025 Jun 30;37(1):32. doi: 10.1186/s43046-025-00291-1.
3
Hypericin Suppresses SARS-CoV-2 Replication and Synergizes with Antivirals via Dual Targeting of RdRp and 3CLpro.
Microorganisms. 2025 Apr 27;13(5):1004. doi: 10.3390/microorganisms13051004.
4
Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.
J Med Virol. 2025 May;97(5):e70377. doi: 10.1002/jmv.70377.
5
Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.
Cureus. 2024 Dec 15;16(12):e75722. doi: 10.7759/cureus.75722. eCollection 2024 Dec.
6
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.
PLoS Pathog. 2024 Oct 15;20(10):e1012624. doi: 10.1371/journal.ppat.1012624. eCollection 2024 Oct.
7
COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches.
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):63-72. doi: 10.55729/2000-9666.1399. eCollection 2024.
8
Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy.
Respir Med Case Rep. 2024 Sep 2;51:102104. doi: 10.1016/j.rmcr.2024.102104. eCollection 2024.
9
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.
Transplant Cell Ther. 2024 Nov;30(11):1108.e1-1108.e11. doi: 10.1016/j.jtct.2024.08.010. Epub 2024 Aug 22.
10
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.
Infect Dis Ther. 2024 Sep;13(9):2035-2052. doi: 10.1007/s40121-024-01023-z. Epub 2024 Aug 3.
本文引用的文献
1
Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
J Med Virol. 2022 Oct;94(10):4780-4791. doi: 10.1002/jmv.27927. Epub 2022 Jun 16.
2
Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients.
Lancet Microbe. 2022 Aug;3(8):e559. doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.
3
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab.
Clin Microbiol Infect. 2022 Sep;28(9):1297-1299. doi: 10.1016/j.cmi.2022.05.002. Epub 2022 May 17.
4
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.
Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
5
The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition.
Cell Res. 2022 May;32(5):498-500. doi: 10.1038/s41422-022-00640-y. Epub 2022 Mar 15.
6
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
7
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
JAMA Intern Med. 2022 Feb 1;182(2):153-162. doi: 10.1001/jamainternmed.2021.7024.
8
Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.
J Infect Dis. 2022 Apr 1;225(7):1118-1123. doi: 10.1093/infdis/jiab622.
9
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
10
SARS-CoV-2 Variants in Patients with Immunosuppression.
N Engl J Med. 2021 Aug 5;385(6):562-566. doi: 10.1056/NEJMsb2104756.
Zotero 插件